Broadcom builds on massive gains with more massive gains

The S&P 500 briefly dipped into negative territory and tariff-sensitive stocks swung from big gains to big losses after the Supreme Court declined to give a ruling on tariffs imposed by President Donald Trump under the IEEPA.

A basket of “Trump Tariff Losers” stocks compiled by UBS, which includes Under Armour, American Eagle, Yeti, Mattel, and Deckers Outdoor, was up as much as 1.5% in early trading before falling as much as 1.7% after news of the lack of news surfaced.

The good news is that for the market as a whole (and even this group in particular), the pain seems to have been short-lived, with both bouncing back to erase losses.

It’s a decent little snapshot or case study to show that, yes, as prediction markets imply, the stock market is pricing in tariff relief.

Amazon Pharmacy announced Friday that it will offer Novo Nordisk’s recently approved weight-loss pill Wegovy, the newest frontier in the drugmaker’s push toward direct-to-consumer options.

Amazon said it will offer delivery for the pill through insurance and cash-pay options. Novo’s cash-pay price for the pill is $149 a month — less than half of what its injectables cost through the same channel.

Novo has partnered with big-box stores like Costco and Walmart as well as several big telehealth companies, including Ro, Weight Watchers, and LifeMD, to distribute the pill. This comes as the Danish pharma giant is trying to regain ground after Eli Lilly surpassed it in market share, in large part because of its early emphasis on direct-to-consumer channels.

The Food and Drug Administration approved Novo’s weight-loss pill in December, making it the first approved weight-loss pill to go to market. It has the same active ingredient, semaglutide, as its injectable products, Ozempic and Wegovy. Lilly’s oral version, orforglipron, is expected to come to market later this year.

A rare double upgrade from JPMorgan has Southwest Airlines taking off on Friday morning, with shares up 4% shortly after the market opened.

The firm upgraded Southwest from “underweight” to “overweight” and hiked its price target from $36 to $60. According to analyst Jamie Baker, the potential for earnings-per-share guidance of $5 is “attractively probable” in 2026 — a figure that would “handily dwarf” the Wall Street consensus.

“Southwest possesses the industry’s deepest track record of profitability, an investment grade balance sheet, and a loyal customer base,” Baker wrote, adding that recent hiccups and slow adaptation is stabilizing, and revenue-driving initiatives like bag fees are “progressing as planned.”

Bag fees helped drive the airline to record third-quarter revenue in October. Later this month, the carrier will roll out assigned seating, which will open up new seating tier categories (and more premium ticket options).